acamprosate has been researched along with Brain Ischemia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bähr, M; Doeppner, TR; Hermann, DM; Kaltwasser, B; Kilic, E; Pehlke, JR; Schlechter, J | 1 |
Engelhard, K; Kochs, E; Lu, H; Möllenberg, O; Werner, C; Zieglgänsberger, W | 1 |
2 other study(ies) available for acamprosate and Brain Ischemia
Article | Year |
---|---|
The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration.
Topics: Acamprosate; Animals; Blood-Brain Barrier; Brain Ischemia; Calpain; Enzyme Activation; Interleukin-12 Subunit p35; JNK Mitogen-Activated Protein Kinases; Male; Mice; Neovascularization, Physiologic; Nerve Regeneration; Neuroprotective Agents; Oxidative Stress; Receptors, N-Methyl-D-Aspartate; Recovery of Function; STAT6 Transcription Factor; Taurine | 2015 |
[The neuroprotective effect of the glutamate antagonist acamprosate following experimental cerebral ischemia. A study with the lipid peroxidase inhibitor u-101033e].
Topics: Acamprosate; Alcohol Deterrents; Anesthetics, Intravenous; Animals; Brain Ischemia; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Fentanyl; Lipid Peroxidation; Male; Neuroprotective Agents; Peroxidase; Pyrimidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Taurine | 2000 |